Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Neurocrine Biosciences News

    124,20 € 0,00% +0,00 €
    08:00:48 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 900964
    ISIN: US64125C1099
    US-Symbol: NBIX
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 8,62
    ME6CN9

    Neurocrine Biosciences News

    10.04.24 - PR Newswire
    Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
    Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results PR Newswire
    03.04.24 - PR Newswire
    Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
    Neurocrine Biosciences Announces First-​Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder PR Newswire
    28.03.24 - PR Newswire
    Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
    Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-​Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire
    11.03.24 - PR Newswire
    Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
    Neurocrine Biosciences to Participate at Virtual Investor Conferences in March PR Newswire
    27.02.24 - PR Newswire
    Neurocrine Biosciences to Participate at Investor Conferences in March
    Neurocrine Biosciences to Participate at Investor Conferences in March PR Newswire
    13.02.24 - wallstreet:online Zentralredaktion
    Tech-Analyse: Nvidia und elf weitere Wachstumsperlen, deren KGV für sich spricht!
    Die Nvidia-​Aktie hat ihren Wert im vergangenen Jahr mehr als verdoppelt. Angesichts dieses Laufes könnte man meinen, die Aktie wäre alles andere als günstig bewertet. Das sei ...
    07.02.24 - PR Newswire
    Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
    Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 PR Newswire
    17.01.24 - PR Newswire
    Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
    Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results PR Newswire
    02.01.24 - PR Newswire
    Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
    05.12.23 - PR Newswire
    Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
    Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia PR Newswire
    01.12.23 - PR Newswire
    Neurocrine Biosciences to Host Analyst Day on December 5, 2023
    Neurocrine Biosciences to Host Analyst Day on December 5, 2023 PR Newswire
    13.11.23 - PR Newswire
    Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
    Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation PR Newswire
    09.11.23 - PR Newswire
    Neurocrine Biosciences Provides Development Pipeline Update
    Neurocrine Biosciences Provides Development Pipeline Update PR Newswire
    08.11.23 - PR Newswire
    Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
    Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia PR Newswire
    08.11.23 - PR Newswire
    Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference
    Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference PR Newswire
    02.11.23 - PR Newswire
    Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
    Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease ...
    31.10.23 - PR Newswire
    Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
    Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance PR Newswire
    10.10.23 - PR Newswire
    Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results
    Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results PR Newswire
    05.10.23 - PR Newswire
    Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
    Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary ...
    21.09.23 - PR Newswire
    Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023
    Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023 PR Newswire

    Newssuche

    Videos

    newspaper
    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »